164 related articles for article (PubMed ID: 27649658)
21. Circulating epithelial cells as potential biomarkers for detection of recurrence in patients of papillary thyroid carcinoma with positive serum anti-thyroglobulin antibody.
Li YR; Tseng CP; Hsu HL; Lin HC; Chen YA; Chen ST; Liou MJ; Lin JD
Clin Chim Acta; 2018 Feb; 477():74-80. PubMed ID: 29229463
[TBL] [Abstract][Full Text] [Related]
22. Increased type 3 deiodinase expression in papillary thyroid carcinoma.
Romitti M; Wajner SM; Zennig N; Goemann IM; Bueno AL; Meyer EL; Maia AL
Thyroid; 2012 Sep; 22(9):897-904. PubMed ID: 22823995
[TBL] [Abstract][Full Text] [Related]
23. miR-146a and miR-146b in the diagnosis and prognosis of papillary thyroid carcinoma.
Qiu Z; Li H; Wang J; Sun C
Oncol Rep; 2017 Nov; 38(5):2735-2740. PubMed ID: 29048684
[TBL] [Abstract][Full Text] [Related]
24. Expression of cancer stem cell markers is more frequent in anaplastic thyroid carcinoma compared to papillary thyroid carcinoma and is related to adverse clinical outcome.
Yun JY; Kim YA; Choe JY; Min H; Lee KS; Jung Y; Oh S; Kim JE
J Clin Pathol; 2014 Feb; 67(2):125-33. PubMed ID: 23986551
[TBL] [Abstract][Full Text] [Related]
25. Coexistence of Graves' disease, papillary thyroid carcinoma and unilateral benign struma ovarii: case report and review of the literature.
Anastasilakis AD; Ruggeri RM; Polyzos SA; Makras P; Molyva D; Campennì A; Gkiomisi A; Balaris C; Fotiadis PP; Tuccari G; Papachatzopoulos S
Metabolism; 2013 Oct; 62(10):1350-6. PubMed ID: 23806737
[TBL] [Abstract][Full Text] [Related]
26. BRAF-Activated Long Noncoding RNA Modulates Papillary Thyroid Carcinoma Cell Proliferation through Regulating Thyroid Stimulating Hormone Receptor.
Zheng H; Wang M; Jiang L; Chu H; Hu J; Ning J; Li B; Wang D; Xu J
Cancer Res Treat; 2016 Apr; 48(2):698-707. PubMed ID: 26323637
[TBL] [Abstract][Full Text] [Related]
27. TSH receptor status of thyroid neoplasms--TaqMan RT-PCR analysis of archival material.
Sheils OM; Sweeney EC
J Pathol; 1999 May; 188(1):87-92. PubMed ID: 10398146
[TBL] [Abstract][Full Text] [Related]
28. Thyroid-Stimulating Hormone, Thyroid Hormones, and Risk of Papillary Thyroid Cancer: A Nested Case-Control Study.
Huang H; Rusiecki J; Zhao N; Chen Y; Ma S; Yu H; Ward MH; Udelsman R; Zhang Y
Cancer Epidemiol Biomarkers Prev; 2017 Aug; 26(8):1209-1218. PubMed ID: 28377419
[No Abstract] [Full Text] [Related]
29. Prognostic implications of miR-146b expression and its functional role in papillary thyroid carcinoma.
Chou CK; Yang KD; Chou FF; Huang CC; Lan YW; Lee YF; Kang HY; Liu RT
J Clin Endocrinol Metab; 2013 Feb; 98(2):E196-205. PubMed ID: 23264400
[TBL] [Abstract][Full Text] [Related]
30. Association between TSHR gene methylation and papillary thyroid cancer: a meta-analysis.
Qu M; Wan S; Ren B; Wu H; Liu L; Shen H
Endocrine; 2020 Sep; 69(3):508-515. PubMed ID: 32279226
[TBL] [Abstract][Full Text] [Related]
31. Overexpression of cytokeratin 17 is associated with the development of papillary thyroid carcinoma and the presence of lymph node metastasis.
Kim HS; Lee JJ; Do SI; Kim K; Do IG; Kim DH; Chae SW; Sohn JH
Int J Clin Exp Pathol; 2015; 8(5):5695-701. PubMed ID: 26191283
[TBL] [Abstract][Full Text] [Related]
32. MicroRNA-96 plays an oncogenic role by targeting FOXO1 and regulating AKT/FOXO1/Bim pathway in papillary thyroid carcinoma cells.
Song HM; Luo Y; Li DF; Wei CK; Hua KY; Song JL; Xu H; Maskey N; Fang L
Int J Clin Exp Pathol; 2015; 8(9):9889-900. PubMed ID: 26617698
[TBL] [Abstract][Full Text] [Related]
33. Overexpression of Forkhead box Q1 correlates with poor prognosis in papillary thyroid carcinoma.
Li Y; Wang HQ; Wang AC; Li YX; Ding SS; An XJ; Shi HY
Clin Endocrinol (Oxf); 2019 Feb; 90(2):334-342. PubMed ID: 30378716
[TBL] [Abstract][Full Text] [Related]
34. Expression and Clinical Significance of Thyroid-stimulating hormone receptor in the Subtypes of Papillary thyroid carcinomas.
Shen W; Zhang S; Li Q
Pak J Med Sci; 2023; 39(1):198-202. PubMed ID: 36694763
[TBL] [Abstract][Full Text] [Related]
35. Long noncoding RNA PVT1 modulates thyroid cancer cell proliferation by recruiting EZH2 and regulating thyroid-stimulating hormone receptor (TSHR).
Zhou Q; Chen J; Feng J; Wang J
Tumour Biol; 2016 Mar; 37(3):3105-13. PubMed ID: 26427660
[TBL] [Abstract][Full Text] [Related]
36. [Value of VEGF-C, VEGF-D and VEGFR-3 levels combined with serum TSH in diagnosis of papillary thyroid carcinoma].
Huang J; Li Y; Xue G; Zhang W; Li S; Zhang J; Wu J
Nan Fang Yi Ke Da Xue Xue Bao; 2014 Dec; 34(12):1814-7, 1821. PubMed ID: 25537909
[TBL] [Abstract][Full Text] [Related]
37. Expression of the membrane mucins MUC4 and MUC15, potential markers of malignancy and prognosis, in papillary thyroid carcinoma.
Nam KH; Noh TW; Chung SH; Lee SH; Lee MK; Hong SW; Chung WY; Lee EJ; Park CS
Thyroid; 2011 Jul; 21(7):745-50. PubMed ID: 21615302
[TBL] [Abstract][Full Text] [Related]
38. [The expression and significance of trefoil factor 3 and SDF-1/CXCR4 biological axis in papillary thyroid carcinoma].
Xue G; Huang J; Zhang H; Zhang W; Wu J; Shang X
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2014 Jan; 28(2):108-12. PubMed ID: 24738314
[TBL] [Abstract][Full Text] [Related]
39. Expression of sodium/iodide transporters and thyroid stimulating hormone receptors in thyroid cancer patients and its correlation with iodine nutrition status and pathology.
Li J; Dong JN; Zhao Z; Lv Q; Yun B; Liu JQ; Cai XY
Eur Rev Med Pharmacol Sci; 2018 Jul; 22(14):4573-4580. PubMed ID: 30058701
[TBL] [Abstract][Full Text] [Related]
40. LncRNA SNHG12 promotes the proliferation and metastasis of papillary thyroid carcinoma cells through regulating wnt/β-catenin signaling pathway.
Ding S; Qu W; Jiao Y; Zhang J; Zhang C; Dang S
Cancer Biomark; 2018; 22(2):217-226. PubMed ID: 29630517
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
